Evidence map›Paper›PMID 31665763›Full record

ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2019

Risk factors for development of aminoglycoside resistance among gram-negative rods.

Stefan E Richter, Loren Miller, Jack Needleman, Daniel Z Uslan, Douglas Bell, Karol Watson, Romney Humphries, James A McKinnell

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Multidrug resistance in pathogenicFrontiers in veterinary science · 2024
    Article
  2. Identifying alternative antibiotics that elute from calcium sulfate beads for treatment of orthopedic infections.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Stefan E RichterDepartment of Cardiology, University of California, Los Angeles, and NIH BD2K Center of Excellence at UCLA, Los Angeles, CA.
Loren MillerInfectious Disease Clinical Outcome Research Unit, Los Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, CA.
Jack NeedlemanDepartment of Health Policy and Management, University of California, Los Angeles, Los Angeles, CA.
Daniel Z UslanDepartment of Infectious Disease, University of California, Los Angeles, Los Angeles, CA.
Douglas BellDepartment of Internal Medicine, University of California, Los Angeles, Los Angeles, CA.
Karol WatsonDepartment of Cardiology, University of California, Los Angeles, and NIH BD2K Center of Excellence at UCLA, Los Angeles, CA.
Romney HumphriesDepartment of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, and Accelerate Diagnostics, Tucson, AZ.
James A McKinnellInfectious Disease Clinical Outcome Research Unit Los Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, CA.
University of California, Los Angeles · USThe Lundquist Institute · USAccelerated Medical Diagnostics (United States) · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
TRAININGU54GM114833 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LINDSEY, MERRY L., PING, PEIPEI · 2014 to 2017
$13.8M
CARDIOVASCULAR SCIENTIST TRAINING PROGRAMT32HL007895 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIVKUMAR, KALYANAM, WATSON, KAROL E · 1998 to 2023
$9.2M
NCATS NIH HHS UL1 TR001881NHLBI NIH HHS T32 HL007895NIGMS NIH HHS U54 GM114833
6 · The paper itself

Abstract

purposeDevelopment of scoring systems to predict the risk of aminoglycoside resistance and to guide therapy is described.

methodsInfections due to aminoglycoside-resistant gram-negative rods (AR-GNRs) are increasingly common and associated with adverse outcomes; selection of effective initial antibiotic therapy is necessary to reduce adverse consequences and shorten length of stay. To determine risk factors for AR-GNR recovery from culture, cases of GNR infection among patients admitted to 2 institutions in a major academic hospital system during the period 2011-2016 were retrospectively analyzed. Gentamicin and tobramycin resistance (GTR-GNR) and amikacin resistance (AmR-GNR) patterns were analyzed separately. A total of 26,154 GNR isolates from 12,516 patients were analyzed, 6,699 of which were GTR, and 2,467 of which were AmR.

resultsIn multivariate analysis, risk factors for GTR-GNR were presence of weight loss, admission from another medical or long-term care facility, a hemoglobin level of <11 g/dL, receipt of any carbapenem in the prior 30 days, and receipt of any fluoroquinolone in the prior 30 days (C statistic, 0.63). Risk factors for AmR-GNR were diagnosis of cystic fibrosis, male gender, admission from another medical or long-term care facility, ventilation at any point prior to culture during the index hospitalization, receipt of any carbapenem in the prior 30 days, and receipt of any anti-MRSA agent in the prior 30 days (C statistic, 0.74). Multinomial and ordinal models demonstrated that the risk factors for the 2 resistance patterns differed significantly.

conclusionA scoring system derived from the developed risk prediction models can be applied by providers to guide empirical antimicrobial therapy for treatment of GNR infections.

Indexed as

Drug Resistance, BacterialAcademic Medical CentersAdultAgedAged, 80 and overAlgorithmsAminoglycosidesAnti-Bacterial AgentsAntimicrobial StewardshipCarbapenemsFemaleGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansMaleMiddle AgedAminoglycosidesAnti-Bacterial AgentsCarbapenemsaminoglycosidesantimicrobial resistanceantimicrobial stewardshipclinical decision makinggram-negative rods

Identifiers

PMID31665763
PMCPMC7170722
OpenAlexW2982578530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.